Neoadjuvant chemotherapy for breast cancer: Functional tumor volume by MR imaging predicts recurrencefree survival-results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIAL

Radiology

Volumn 279, Issue 1, 2016, Pages 44-55

  Hylton, Nola M ^a   Gatsonis, Constantine A ^b,c   Rosen, Mark A ^d   Lehman, Constance D ^e   Newitt, David C ^a   Partridge, Savannah C ^e   Bernreuter, Wanda K ^f   Pisano, Etta D ^g   Morris, Elizabeth A ^h   Weatherall, Paul T ⁱ   Polin, Sandra M ^j   Newstead, Gillian M ^k   Marques, Helga S ^b,c   Esserman, Laura J ^a   Schnall, Mitchell D ^c,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BROWN UNIVERSITY   (United States)

^c AMERICAN COLLEGE OF RADIOLOGY   (United States)

^d HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^f University of Alabama at Birmingham   (United States)

^g MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^h MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

ⁱ UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^j GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k UNIVERSITY OF CHICAGO   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HORMONE RECEPTOR; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CLINICAL TRIAL (TOPIC); FEMALE; FUNCTIONAL TUMOR VOLUME; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOLOGICAL PARAMETERS; PATHOLOGIC COMPLETE RESPONSE; PREDICTION; PRIORITY JOURNAL; RACE DIFFERENCE; RECURRENCE FREE SURVIVAL; RESIDUAL CANCER BURDEN; TREATMENT RESPONSE; TUMOR VOLUME; UNIVARIATE ANALYSIS; BREAST NEOPLASMS; CLINICAL TRIAL; DISEASE FREE SURVIVAL; FOLLOW UP; LARGE CORE NEEDLE BIOPSY; MIDDLE AGED; MULTICENTER STUDY; NEOADJUVANT THERAPY; PATHOLOGY; PREDICTIVE VALUE; PROCEDURES; TREATMENT OUTCOME; UNITED STATES;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY, LARGE-CORE NEEDLE; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; NEOADJUVANT THERAPY; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME; TUMOR BURDEN; UNITED STATES;

EID: 84962800293     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.2015150013     Document Type: Article

References (30)

1. Croshaw R, Shapiro-Wright H, Svensson E, Erb K, Julian T. Accuracy of clinical examination, digital mammogram, ultrasound, and MRI in determining postneoadjuvant pathologic tumor response in operable breast cancer patients. Ann Surg Oncol 2011;18(11): 3160-3163.
2. Londero V, Bazzocchi M, Del Frate C, et al. Locally advanced breast cancer: comparison of mammography, sonography and MR imaging in evaluation of residual disease in women receiving neoadjuvant chemotherapy. Eur Radiol 2004;14(8):1371-1379.
3. Shin HJ, Kim HH, Ahn JH, et al. Comparison of mammography, sonography, MRI and clinical examination in patients with locally advanced or infammatory breast cancer who underwent neoadjuvant chemotherapy. Br J Radiol 2011;84(1003):612-620.
4. Yeh E, Slanetz P, Kopans DB, et al. Prospective comparison of mammography, sonogra-phy, and MRI in patients undergoing neoadju-vant chemotherapy for palpable breast cancer. AJR Am J Roentgenol 2005;184(3):868-877.
5. Akazawa K, Tamaki Y, Taguchi T, et al. Preoperative evaluation of residual tumor extent by three-dimensional magnetic resonance imaging in breast cancer patients treated with neoadjuvant chemotherapy. Breast J 2006;12(2):130-137.
6. Montemurro F, Martincich L, De Rosa G, et al. Dynamic contrast-enhanced MRI and sonography in patients receiving primary chemotherapy for breast cancer. Eur Radiol 2005;15(6):1224-1233.
7. Weatherall PT, Evans GF, Metzger GJ, Sab-orrian MH, Leitch AM. MRI vs. histologic measurement of breast cancer following chemotherapy: comparison with x-ray mam-mography and palpation. J Magn Reson Imaging 2001;13(6):868-875.
8. Rosen EL, Blackwell KL, Baker JA, et al. Accuracy of MRI in the detection of residual breast cancer after neoadjuvant chemotherapy. AJR Am J Roentgenol 2003;181 (5):1275-1282.
9. Ko ES, Han BK, Kim RB, et al. Analysis of factors that infuence the accuracy of magnetic resonance imaging for predicting response after neoadjuvant chemotherapy in locally advanced breast cancer. Ann Surg Oncol 2013;20(8):2562-2568.
10. Lobbes MB, Prevos R, Smidt M, et al. The role of magnetic resonance imaging in assessing residual disease and pathologic complete response in breast cancer patients receiving neoadjuvant chemotherapy: a systematic review. Insights Imaging 2013;4(2): 163-175.
11. Partridge SC, Gibbs JE, Lu Y, et al. MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival. AJR Am J Roentgenol 2005;184(6):1774-1781.
12. Lobbes MB. Treatment response evaluation by MRI in breast cancer patients receiving neoadjuvant chemotherapy: there is more than just pathologic complete response prediction. Breast Cancer Res Treat 2012;136(1): 313-314.
13. Marinovich ML, Houssami N, Macaskill P, et al. Meta-analysis of magnetic resonance imaging in detecting residual breast cancer after neoadjuvant therapy. J Natl Cancer Inst 2013;105(5):321-333.
14. Esserman LJ, Berry DA, Cheang MC, et al. Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat 2012;132(3):1049-1062.
15. Hylton NM, Blume JD, Bernreuter WK, et al. Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy-results from ACRIN 6657/I-SPY TRIAL. Radiology 2012; 263(3):663-672.
16. Hylton NM. Vascularity assessment of breast lesions with gadolinium-enhanced MR imaging. Magn Reson Imaging Clin N Am 1999; 7(2):411-420, x.
17. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45(2):228-247.
18. Esserman LJ, Berry DA, DeMichele A, et al. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRI-AL-CALGB 150007/150012, ACRIN 6657. J Clin Oncol 2012;30(26):3242-3249.
19. Symmans WF, Peintinger F, Hatzis C, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 2007;25(28):4414-4422.
20. Hudis CA, Barlow WE, Costantino JP, et al. Proposal for standardized defnitions for ef-fcacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol 2007; 25(15):2127-2132.
21. Uno H, Cai T, Pencina MJ, D'Agostino RB, Wei LJ. On the C-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data. Stat Med 2011;30(10):1105-1117.
22. Hosmer DW Jr, Lemeshow S, May S. Applied survival analysis: regression modeling of time to event data. 2nd ed. New York, NY: Wiley, 2008.
23. Wasser K, Sinn HP, Fink C, et al. Accuracy of tumor size measurement in breast cancer using MRI is infuenced by histological regression induced by neoadjuvant chemotherapy. Eur Radiol 2003;13(6):1213-1223.
24. Denis F, Desbiez-Bourcier AV, Chapiron C, Arbion F, Body G, Brunereau L. Contrast enhanced magnetic resonance imaging un-derestimates residual disease following neoadjuvant docetaxel based chemotherapy for breast cancer. Eur J Surg Oncol 2004;30(10):1069-1076.
25. Warren RM, Bobrow LG, Earl HM, et al. Can breast MRI help in the management of women with breast cancer treated by neoadjuvant chemotherapy? Br J Cancer 2004;90(7):1349-1360.
26. King V, Goldfarb SB, Brooks JD, et al. Effect of aromatase inhibitors on background parenchymal enhancement and amount of fbroglandular tissue at breast MR imaging. Radiology 2012;264(3):670-678.
27. King V, Kaplan J, Pike MC, et al. Impact of tamoxifen on amount of fbroglandular tissue, background parenchymal enhancement, and cysts on breast magnetic resonance imaging. Breast J 2012;18(6):527-534.
28. Oksa S, Parkkola R, Luukkaala T, Mäen-pää J. Breast magnetic resonance imaging fndings in women treated with toremifene for premenstrual mastalgia. Acta Radiol 2009;50(9):984-989.
29. Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007;13(8):2329-2334.
30. Prowell T. Guidance to Industry. Pathologic Complete Response in Neoadjuvant Treatment of High-Risk Early-Stage Breast Cancer: Use as an Endpoint to Support Accelerated Approval. 2012.